Cilostazol in a Child With Moyamoya Disease

Moyamoya Disease (MMD) is a chronic and progressive cerebrovascular condition characterized by the pathological stenosis of the terminal internal carotid arteries and their proximal branches. It was already known that surgical revascularization procedures, such as pial synangiosis, serve as the primary intervention to mitigate the high risk of ischemic and hemorrhagic strokes in affected children. While these surgical techniques improve macrovascular perfusion, many pediatric patients continue to experience debilitating transient neurologic events despite successful operative outcomes. Current clinical guidelines lack robust evidence regarding the safety or efficacy of pharmacological agents to manage these persistent symptoms in the pediatric population. Although recent investigations have validated the utility of Phosphodiesterase 3 (PDE3) inhibitors in adult cohorts, their role in treating younger patients remains largely unexplored. The lack of standardized nonsurgical protocols for managing postoperative symptoms in children represents a significant hurdle in comprehensive MMD care. This absence of evidence motivated the exploration of cilostazol as a potential pharmacological solution for refractory symptoms in a young patient.

This clinical investigation evaluates the safety and therapeutic efficacy of cilostazol in a nine-year-old female patient diagnosed with Moyamoya Disease (MMD) following a major right Middle Cerebral Artery (MCA) stroke. The primary objective was to determine if pharmacological intervention could suppress frequent transient neurologic events that persisted after the patient underwent bilateral pial synangiosis. Researchers focused on addressing specific focal symptoms, including sudden onset dysarthria and left-sided drooling, which occurred despite surgical revascularization. The study aimed to provide a viable alternative for patients who do not respond to conventional postoperative management strategies like blood pressure augmentation or antiseizure medications. By documenting the clinical trajectory of this patient, the authors sought to establish a preliminary framework for using Phosphodiesterase 3 (PDE3) inhibitors in pediatric neurology. The investigation also aimed to identify the necessity of dosing adjustments to maintain long-term symptom suppression in a growing child. This absence of evidence motivated the detailed recording of the patient's response to varying concentrations of the medication over time.

The medical team conducted a longitudinal case study of a nine-year-old girl who presented with a large-scale ischemic stroke in the right Middle Cerebral Artery (MCA) territory. Following the diagnosis of Moyamoya Disease (MMD), the patient received bilateral pial synangiosis, a surgical technique designed to induce indirect revascularization by placing a donor artery onto the brain surface. When the patient began experiencing recurrent transient neurologic events post-surgery, the clinicians first implemented a regimen of antiseizure medications to rule out post-stroke epilepsy. They simultaneously used blood pressure augmentation to enhance cerebral perfusion through the newly formed collateral vessels and the stenotic internal carotid arteries. After these initial interventions failed to reduce the frequency of the episodes, the team introduced cilostazol, a selective inhibitor of Phosphodiesterase 3 (PDE3) with both antiplatelet and vasodilatory properties. The researchers monitored the patient's clinical status closely, recording the frequency of dysarthria and motor deficits while adjusting the cilostazol dosage to optimize the therapeutic effect.

The administration of cilostazol resulted in the immediate and complete cessation of the patient's frequent transient neurologic events, which had previously resisted all other forms of treatment. Initial clinical observations showed that the nine-year-old girl remained symptom-free for a significant period following the start of the Phosphodiesterase 3 (PDE3) inhibitor therapy. However, the researchers noted a brief recurrence of the neurologic episodes, including dysarthria and drooling, during the subsequent follow-up phase. This recurrence prompted a strategic adjustment of the cilostazol dosing, which successfully eliminated the symptoms once again and restored clinical stability. The patient demonstrated excellent tolerance to the medication, with no evidence of adverse hematological effects or systemic complications during the study period. These results indicate that the pharmacological management of microvascular flow can effectively supplement the macrovascular improvements provided by pial synangiosis. The study suggests that cilostazol could bridge the therapeutic gap for pediatric patients who continue to experience ischemia-related events after surgical intervention.

This case indicates that cilostazol may serve as a safe and effective adjunctive treatment for pediatric patients suffering from Moyamoya Disease (MMD). The successful resolution of refractory transient neurologic events suggests that Phosphodiesterase 3 (PDE3) inhibition provides a functional mechanism for stabilizing cerebral perfusion post-surgery. These observations underscore the necessity for rigorous, prospective clinical trials to establish standardized dosing and safety protocols for children. Clinicians should consider this pharmacological approach when traditional blood pressure management and surgical revascularization do not fully eliminate ischemic symptoms. The findings expand the therapeutic landscape for pediatric cerebrovascular disorders by bridging the gap between adult-centric data and pediatric clinical needs. Future research must focus on the long-term outcomes and potential side effects of chronic cilostazol use in developing populations. This report serves as a foundational stepping stone toward expanding the evidence-based treatment options available for pediatric cerebrovascular disorders.